Investment Rating - The investment rating for the company is "Buy" with an expected return exceeding 10% relative to the CSI 300 index over the next six months [22]. Core Views - The company's self-operated business shows steady growth, and its wealth management maintains an industry-leading position. With the gradual improvement of the economic fundamentals and the moderate rise of the equity market, the company's valuation is expected to increase alongside market trading enthusiasm and policy reforms [10]. Financial Performance - In 2024, the company achieved revenue of 41.466 billion yuan, a growth of 13.37%, and a net profit attributable to shareholders of 15.351 billion yuan, an increase of 20.40%. The basic earnings per share were 1.62 yuan, up by 20.00% [1]. - The return on equity (ROE) for 2023 was 9.24%, an increase of 1.12 percentage points compared to the previous year [1]. Wealth Management - The company reported net income from brokerage services of 6.447 billion yuan, an increase of 8.19%. By the end of 2024, the company had 177.639 billion yuan in cash, a year-on-year increase of 18.17%, primarily due to increased client funds [2]. - The number of financial products (excluding cash management products) reached 16,760, a growth of 51.40%, with a sales scale of 503.991 billion yuan, up by 13.63% [2]. Investment Banking - The company achieved net income from investment banking of 2.097 billion yuan, a decrease of 30.95%. The equity underwriting scale was 54.897 billion yuan, down by 39.87%, ranking second in the industry [3]. - The bond underwriting scale reached 1,296.048 billion yuan, an increase of 3.12%, ranking third in the industry [3]. Asset Management - The net income from asset management was 4.146 billion yuan, a decrease of 2.58%. The asset management scale grew significantly to 556.267 billion yuan, an increase of 16.98% [4]. International Business - The company's international business revenue surged to 14.340 billion yuan, an increase of 80.93%, accounting for 34.58% of total revenue [9]. Future Earnings Projections - The projected basic earnings per share for 2025, 2026, and 2027 are 1.73 yuan, 1.80 yuan, and 1.95 yuan, respectively. The projected net asset per share for the same years is 17.60 yuan, 18.91 yuan, and 20.37 yuan [10].

Core Viewpoint - The report from Huatai Securities indicates that fiscal easing has intensified in March, with significant support for economic growth from expanded fiscal policies [1] Fiscal Policy Analysis - In the first quarter, the broad fiscal expenditure (general public budget + government funds) increased by 5.6% year-on-year, surpassing the nominal GDP growth rate of 4.6% [1] - The growth rate of broad fiscal expenditure in March rebounded sharply to 10.1% from 2.9% in January-February, indicating strong spending momentum [1] - Notable increases in spending were observed in infrastructure-related areas such as agriculture, forestry, water affairs, and energy conservation and environmental protection, aligning with the high growth in infrastructure investment in March [1] Fiscal Deficit and Future Outlook - The broad fiscal deficit in March reached 1.7 trillion yuan, an increase of 366.1 billion yuan compared to the same period last year, reflecting an intensified fiscal policy expansion [1] - Looking ahead, the implementation of tariff policies in April may disrupt exports, highlighting the necessity for further fiscal easing in the second quarter [1] - The stability of fiscal revenue growth is crucial for the sustainability of fiscal expansion [1]

Core Viewpoint - The company, Yihe Jiaye, is a leading domestic manufacturer of non-invasive respiratory machines and ventilation masks, with significant growth in revenue and market share, particularly in the U.S. and European markets, following the end of the inventory clearance cycle in the U.S. respiratory machine market [1][5][7]. Company Overview - Established in 2001, the company has developed a comprehensive product line for respiratory health, including home non-invasive ventilators, masks, and monitoring devices, and has received multiple certifications such as NMPA, FDA, and CE [2]. - The company focuses on providing full-cycle treatment solutions for patients with OSA and COPD, covering diagnosis, treatment, and chronic disease management [2]. Research and Development - The company maintains a significant scale of R&D investment, holding 633 domestic patents and 202 international patents as of December 31, 2024, indicating a strong commitment to innovation [3]. Brand and Market Strategy - The company has unified its brand under "Ruimaite" to enhance user recognition and market penetration, planning to change its name and stock abbreviation to align with the new brand [4]. - The company aims to increase brand awareness through various channels, including exhibitions, academic exchanges, and social media marketing [4]. Market Conditions - The U.S. respiratory machine market has returned to normalcy after a period of inventory clearance, with the company’s products entering the market without significant impact from U.S.-China tariff policies [5][6]. - The company has achieved a high level of domestic supply chain security and cost advantages through the localization of core components [6]. Financial Performance - In Q4 2024, the company reported a 9.77% increase in revenue compared to Q3, driven by the recovery of the U.S. market [7]. - The overseas business generated 5.42 billion yuan, accounting for 64.21% of total revenue, while domestic revenue was 3.02 billion yuan, representing 35.79% [7]. Product Performance - The company’s home respiratory therapy business generated 5.27 billion yuan in revenue, while consumables contributed 2.84 billion yuan, with consumables showing a steady increase in proportion [7]. - Consumables saw a year-on-year growth of 46.22%, primarily driven by demand from the U.S. and European markets [8]. Market Share - According to data from Sullivan, the company held a 12.4% global market share for home non-invasive ventilators in 2023, ranking second, and a 30.6% share in the domestic market, ranking first among local brands [8].

Group 1 - Chang'an Fund Management Co., Ltd. has signed a sales agreement with Huatai Securities Co., Ltd. to add Huatai Securities as a sales institution for the Chang'an Xinyue Consumption-Driven Mixed Securities Investment Fund starting from April 18, 2025 [1][2] - Investors can conduct account opening, trading, and other fund-related services through Huatai Securities for the mentioned fund, which has fund codes A: 009958 and C: 009959 [1] - Detailed business rules, fee structures, and other important matters related to the fund can be found in the fund contract, prospectus, and product information summary published by the company [1]

Core Viewpoint - Huatai Securities believes that the S&P 500 index is currently in a downward phase across three economic cycles: the Kitchin cycle (42 months), the Juglar cycle (100 months), and the Kuznets cycle (200 months) [1] Group 1: Economic Cycles - The Kitchin cycle is in a downward state, indicating short-term economic fluctuations [1] - The Juglar cycle is also in a downward phase, suggesting medium-term economic trends are weakening [1] - The Kuznets cycle is at the bottom, reflecting long-term economic patterns that are currently unfavorable [1] Group 2: Market Conditions - Since 2022, global asset correlation characteristics have changed, indicating a shift in market dynamics [1] - The long-term inflation issue is becoming more pronounced, affecting overall economic stability [1] - The gradual emergence of constraints on U.S. debt is confirming the entry into a downward phase of the Kondratiev wave, suggesting prolonged economic challenges [1] Group 3: Investment Implications - The simultaneous downward trends in the Kitchin, Juglar, and Kondratiev cycles indicate a resonant negative outlook for U.S. equities [1]

Group 1 - The Ministry of Commerce announced a 125% tariff on imported goods originating from the United States, defining the origin based on the manufacturing stage [1] - The top ten analog chip companies are predominantly American, with half of them being U.S. companies, indicating a significant reliance on U.S. technology in the analog chip sector [1] - The current domestic production rate of analog chips is approximately 20%, suggesting substantial room for domestic substitution and growth in the market [1] Group 2 - Demand from automotive and industrial sectors is gradually recovering, indicating a positive trend in the industry [1] - The industry is entering a phase of mergers and acquisitions, which is expected to optimize the competitive landscape [1] - The acceleration of domestic substitution is anticipated as the market evolves [1]

近日，东英证券、国证国际、华泰证券、中信建投证券、东吴证券、招商证券国际、西牛证券等发布研 报，持续覆盖全球化开放式社交公司赤子城科技(09911.HK)，给予"买入"评级。 多家证券在研报中表示出对赤子城科技2024年业绩表现的认可。东吴证券表示："公司在2024年交出了 一份'高增长、高壁垒、高潜力'的答卷：通过AI技术赋能社交核心业务，'产品灌木丛+AI引擎'的增长模 式已形成正向循环，未来在社交娱乐生态的纵深拓展值得期待。" 近日，赤子城科技发布2024年度业绩公告，得益于AI赋能，公司全年收入同比增长53.9%至50.9亿元人 民币；经调整EBITDA同增43%至9.6亿元人民币。其中，社交业务收入46亿元人民币，同比增长58%， 其中先发产品MICO、YoHo稳健增长，后发产品TopTop收入同比增长超100%，SUGO收入同比增长超 200%，表现亮眼。创新业务收入4.6亿元人民币，同比增长21.3%，精品游戏全年流水同比增长超80%。 AI赋能业绩强劲增长，核心产品矩阵成型 中信建投证券重点关注了赤子城科技的营收，认为其营收显著增长，社交业务和创新业务均有亮眼表 现，后发产品快速增长，显示出公 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司， 中文公司名稱為華泰證券股份有限公司，在香港以HTSC名義開展業務） 承董事會命 聯席公司秘書 張輝 中國江蘇，2025年4月15日 於本公告日期，董事會成員包括執行董事張偉先生及周易先生；非執行董事丁鋒 先生、陳仲揚先生、柯翔先生、劉長春先生及張金鑫先生；以及獨立非執行董事 王建文先生、王全勝先生、彭冰先生、王兵先生及老建榮先生。 「董事會」 指 本公司之董事會 「本公司」 指 於中華人民共和國以華泰證券股份有限公司的公司名 稱註冊成立的股份有限公司，於2007年12月7日由前身 華泰證券有限責任公司改制而成，在香港以「HTSC」 名義開展業務，根據公司條例第16部以中文獲准名稱 「華泰六八八六股份有限公司」及英文公司名稱「Huatai Securities Co., Ltd.」註冊為註冊非香港公司，其H股於 2015年6月1日在香港聯合交易所有限公司主板上市（ ...

证券Ⅱ 分析师：张洋 登记编码：S0730516040002 zhangyang-yjs@ccnew.com 021-50586627 投行综合竞争力稳固、公募业务快速增长 ——华泰证券(601688)2024 年年报点评 证券研究报告-年报点评 增持(维持) 市场数据(2025-04-10) | 收盘价(元) | 15.54 | | --- | --- | | 一年内最高/最低(元) | 20.48/11.88 | | 沪深 300 指数 | 3,735.12 | | 市净率(倍) | 0.86 | | 总市值(亿元) | 1,402.84 | | 流通市值(亿元) | 1,400.68 | | 基础数据(2024-12-31) | | | 每股净资产(元) | 18.10 | | 总资产(亿元) | 8,142.70 | | 所有者权益(亿元) | 1,916.74 | | 净资产收益率(%) | 9.24 | | 总股本(亿股) | 90.27 | | H 股(亿股) | 17.19 | 个股相对沪深 300 指数表现 资料来源：聚源、中原证券研究所 -11% -1% 9% 19% 29% 39% 49 ...

证券Ⅱ 分析师：张洋 登记编码：S0730516040002 zhangyang-yjs@ccnew.com 021-50586627 投行综合竞争力稳固、公募业务快速增长 ——华泰证券(601688)2024 年年报点评 证券研究报告-年报点评 增持(维持) 市场数据(2025-04-10) | 收盘价(元) | 15.54 | | --- | --- | | 一年内最高/最低(元) | 20.48/11.88 | | 沪深 300 指数 | 3,735.12 | | 市净率(倍) | 0.86 | | 总市值(亿元) | 1,402.84 | | 流通市值(亿元) | 1,400.68 | | 基础数据(2024-12-31) | | | 每股净资产(元) | 18.10 | | 总资产(亿元) | 8,142.70 | | 所有者权益(亿元) | 1,916.74 | | 净资产收益率(%) | 9.24 | | 总股本(亿股) | 90.27 | | H 股(亿股) | 17.19 | 个股相对沪深 300 指数表现 资料来源：聚源、中原证券研究所 -11% -1% 9% 19% 29% 39% 49 ...